Ibrut Nib Plus Retuxi Mab for C L L

Study authors concluded that the combination of ibrut nib plus retuxi mab offers superior progression free survival and overall survival. In addition, a lower rate of grade three or higher treatment related adverse events was reported for the i r combination compared to f c r. These findings are largely in agreement with those from the phase three flare study which found a significant difference in progression free survival between the two treatment arms after a medium follow up of 52 point seven months.